Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 14, 2007

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name: **AMERICAN PHARMACISTS ASSN** 1100 15TH STREET, NW, SUITE 400, WASHINGTON, DC 20005 3. Principal place of business (if different from line 2): Country City: State/Zip(or Country): HOLLAND 4. Contact Name: DAYTONA HUTTON Telephone: 2024297572 E-mail (optional): dhutton@aphanet.org Senate ID #: 3071-12 House ID #: 7. Client Name: X Self TYPE OF REPORT \_\_\_\_ Midyear (January 1 - June 30): 🔲 OR Year End (July 1 - December 31): 🔀 9. Check if this filing amends a previously filed version of this report: 10. Check if this is a Termination Report: 

=> Termination Date: 11. No Lobbying Activity: INCOME OR EXPENSES Complete Either Line 12 OR Line 13 12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000: -\$10,000 or more: => Income (nearest \$20,000);\_ Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000: -\$10,000 or more: X => Expenses (nearest \$20,000): 299,853.00 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Method A. Reporting amounts using LDA definitions only

Page 1

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: BUD (one per page)
- 16. Specific lobbying issues:
- S. 3708 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007 | General Health Agency Funding S. 3660 District of Columbia Appropriations Act, 2007 | H.R. 5647 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007 General Health Agency Funding
- 17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A
Name: POLLEY, CATHERINE

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:

H.R.2841 Medicare Safe Needle Disposal Coverage Act of 2005 H.R. 6111 An act to amend the Internal Revenue Code of 1986 to extend expiring provisions, and for other purposes | Vaccine Reimbursement H.R. 6164 National Institutes of Health Reform Act of 2006 H.R. 1020 National Pain Care Policy Act of 2005

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A
Name: POLLEY, CATHERINE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

#### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:
- S. 2664 Pharmacy Access Improvement (PhAIM) Act of 2006 S. 2551 Prompt Payment of Health Benefits Claims Act of 2006 S. 2563 Pharmacist Access and Recognition in Medicare (PhARM) Act of 2006 Implementation of the Deficit Reduction Act of 2005 Pharmacy Reimbursement Implementation of Medicare Part D CMS 1270-P re: Durable Medical Equipment Competitive Bidding Program I CMS-4119-P re: proposing to allow the Secretary of the DHHS to share Part D claims data for research, analysis, reporting, and public health functions CMS re: Draft 2007 Coordination of Benefits Guidance Medicare Part B payment reforms. H.R. 5182 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2006
- 17. House(s) of Congress and Federal agencies contacted: Centers For Medicare and Medicaid Services (CMS) HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A
Name: POLLEY, CATHERINE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

#### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: PHA (one per page)
- 16. Specific lobbying issues:

H.R. 1652 Access to Legal Pharmaceuticals Act H.R. 1808 Safe Online Drug Act of 2005 H.R. 1815 National Defense Authorization Act for Fiscal Year 2006 I Pharmacy Program H.R. 4769 Prescription Drug Abuse Elimination Act of 2006 H.R. 5122 John Warner National Defense Authorization Act for Fiscal Year 2007 I Pharmacy Program H.R. 5280 Dextromethorphan Distribution Act of 2006 H.R. 5384 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007 I Prescription Drug Importation H.R. 5441 Department of Homeland Security Appropriations Act, 2007 I Prescription Drug Importation S. 334 Pharmaceutical Market Access and Drug Safety Act of 2005 S. 778 Pharmacy Consumer Protection Act of 2005 S. 809 Access to Legal Pharmaceuticals Act S. 2766 John Warner National Defense Authorization Act for Fiscal Year 2007 I Pharmacy Program S. 3807 Enhancing Drug Safety and Innovation Act of 2006 S. 3546 Dietary Supplement and Nonprescription Drug Consumer Protection Act Pharmacy Compounding Counterfeit Drugs Health Information Technology Implementation of the Combat Methamphetamine Epidemic Act of 2005 FDA Draft Compliance Policy Guide 160.900 on pedigree requirements under the Prescription Drug Marketing Act (PDMA) FDA Docket No. 2006N-0283 re: the proposed survey of physicians' perceptions on the impact of early risk communication about medical products DEA Docket No. DEA-2911 re: retail sales of scheduled listed chemical products and self-certification of regulated sellers of scheduled listed chemical products CMS-1321-P re: proposed revisions to the payment policies under the physician fee schedule for calendar year 2007 DEA-287N re the issuing of multiple prescriptions for Schedule II Controlled Substances FDA Re: Draft Compliance Policy Guide 160.900 on pedigree requirements under the Prescription Drug Marketing Act Proposed revisions to the United States Pharmacopeia (USP) General Chapter <797> Pharmaceutical Compounding I Sterile Preparations. H.R. 1539 A bill to amend the Public

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE

Name of each individual who acted as a lobbyist in this issue area:

Name: BOUGH, MARCIE
Covered Official Position (if applicable): N/A
Name: JAMGOCHIAN, HRANT
Covered Official Position (if applicable): N/A
Name: LUNNER, KRISTINA E.
Covered Official Position (if applicable): N/A
Name: POLLEY, CATHERINE
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 14, 2007

Printed Name and Title: DAYTONA A. HUTTON, ADMINISTRATIVE MANAGER -

#### Information Update Page:

Complete ONLY where registration information has changed.

#### LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: BISHOP, SUSAN K Name: WINCKLER, SUSAN C.

#### **ISSUE UPDATE**

24. General lobbying issues previously reported that NO LONGER pertain

### AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

#### FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 14, 2007

Printed Name and Title: -